The Effect of Cyclophospkamide on the Immune Response
- 1 January 1979
- journal article
- review article
- Published by Taylor & Francis in Journal of Immunopharmacology
- Vol. 1 (2) , 127-137
- https://doi.org/10.3109/08923977909026368
Abstract
No abstract availableThis publication has 28 references indexed in Scilit:
- Enhancing effect of low dose cyclophosphamide treatment on the in vitro antibody responseEuropean Journal of Immunology, 1977
- Effects of variation in time and dose of cyclophosphamide injection on delayed hypersensitivity and antibody formationCellular Immunology, 1977
- Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses.The Journal of Experimental Medicine, 1975
- B-cell suppression of delayed hypersensitivity reactionsNature, 1974
- Suppressor cells in normal immunisation as a basic homeostatic phenomenonNature, 1974
- Effects of Cyclophosphamide on Lymphoid Tissues Labelled with 5-Iodo-2-Deoxyuridine-125I and 51CrInternational Archives of Allergy and Immunology, 1972
- Activation of cyclophosphamide in man and animalsCancer, 1971
- Enhancement of Dinitrochlorobenzene (DNCB) Contact Sensitization by Cyclophosphamide in the Guinea PigJournal of Investigative Dermatology, 1967
- EFFECT OF CYCLOPHOSPHAMIDE ON THE HOMOGRAFT RESPONSE IN THE GUINEA PIGTransplantation, 1965
- Effect of Cyclophosphoramide, 6-Mercaptopurine, Actinomycin D and Vincaleukoblastine on the Acquisition of Delayed Hypersensitivity (DNCB Contact Dermatitis) in the Guinea-Pig11From the Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia 4, Pennsylvania.This study was supported in part by U.S.P.H.S. Training Grant 2 G-62.This investigation was carried out during the tenure of a postdoctoral fellowship, held by Dr. Maibach, from the Division of General Medical Sciences, United States Public Health Service.Cyclophosphoramide (Cytoxan®) was supplied by Paul A. Walter, M.D., Mead Johnson Laboratories, Evansville 21, Indiana; 6-mercaptopurine by Donald S. Searle, M.D., Burroughs Wellcome & Co., Tuckahoe, N.Y.; vincaleukoblastine by J. A. Armstrong, M.D., Eli Lilly and Co., Indianapolis 6, Indiana; and Actinomycin D by Elmer Alpert, M.D., Merck Sharp and Dohme, West Point, Pa.Presented at the Twenty-second Annual Meeting of The Society for Investigative Dermatology, Inc., New York, N.Y., June 28, 1961.Journal of Investigative Dermatology, 1961